180
Participants
Start Date
December 3, 2024
Primary Completion Date
January 29, 2027
Study Completion Date
January 29, 2027
Tezepelumab
IMP. Subcutaneous injection. Unit dose strengths 210 mg.
NOT_YET_RECRUITING
Research Site, Budapest
RECRUITING
Research Site, Budapest
RECRUITING
Research Site, Sofia
RECRUITING
Research Site, Sofia
RECRUITING
Research Site, Plovdiv
RECRUITING
Research Site, Nyíregyháza
RECRUITING
Research Site, Pécs
RECRUITING
Research Site, Cadiz
RECRUITING
Research Site, Marseille
RECRUITING
Research Site, Santiago de Compostela
RECRUITING
Research Site, Rozzano
RECRUITING
Research Site, Madrid
RECRUITING
Research Site, Toulouse
RECRUITING
Research Site, Marburg
RECRUITING
Research Site, Padua
RECRUITING
Research Site, Salamanca
RECRUITING
Research Site, Bologna
RECRUITING
Research Site, Düsseldorf
RECRUITING
Research Site, Nantes
NOT_YET_RECRUITING
Research Site, Florence
RECRUITING
Research Site, Pisa
RECRUITING
Research Site, Lille
RECRUITING
Research Site, Chicago
RECRUITING
Research Site, Wiesbaden
RECRUITING
Research Site, Columbia
RECRUITING
Research Site, Pierre-Bénite
RECRUITING
Research Site, Tübingen
RECRUITING
Research Site, Villingen-Schwenningen
RECRUITING
Research Site, Napoli
RECRUITING
Research Site, Poitiers
RECRUITING
Research Site, Newport Beach
RECRUITING
Research Site, Le Kremlin-Bicêtre
RECRUITING
Research Site, Catania
RECRUITING
Research Site, Chestnut Hill
RECRUITING
Research Site, Hamilton
RECRUITING
Research Site, Québec
RECRUITING
Research Site, Québec
RECRUITING
Research Site, Roma
RECRUITING
Research Site, Bialystok
RECRUITING
Research Site, Bydgoszcz
RECRUITING
Research Site, Lodz
RECRUITING
Research Site, Zawadzkie
RECRUITING
Research Site, Barcelona
RECRUITING
Research Site, Barcelona
Lead Sponsor
Collaborators (1)
Fortrea
INDUSTRY
AstraZeneca
INDUSTRY